company background image
AVR

Anteris TechnologiesASX:AVR Stock Report

Market Cap

AU$70.1m

7D

7.8%

1Y

115.3%

Updated

14 Oct, 2021

Data

Company Financials
AVR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

AVR Overview

Anteris Technologies Ltd operates as a structural heart company.

Anteris Technologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Anteris Technologies
Historical stock prices
Current Share PriceAU$8.70
52 Week HighAU$3.41
52 Week LowAU$13.75
Beta0.76
1 Month Change4.07%
3 Month Change3.20%
1 Year Change115.35%
3 Year Changen/a
5 Year Change-78.78%
Change since IPO-88.55%

Recent News & Updates

Jul 08
Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Shareholders of Anteris Technologies Ltd ( ASX:AVR ) will have been dismayed by the negative share price return over...

Shareholder Returns

AVRAU Medical EquipmentAU Market
7D7.8%-1.9%0.1%
1Y115.3%-6.2%19.3%

Return vs Industry: AVR exceeded the Australian Medical Equipment industry which returned -8.2% over the past year.

Return vs Market: AVR exceeded the Australian Market which returned 17.9% over the past year.

Price Volatility

Is AVR's price volatile compared to industry and market?
AVR volatility
AVR Beta0.76
Industry Beta0.57
Market Beta1

Stable Share Price: AVR is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: AVR's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1999n/aWayne Patersonhttps://www.anteristech.com

Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies.

Anteris Technologies Fundamentals Summary

How do Anteris Technologies's earnings and revenue compare to its market cap?
AVR fundamental statistics
Market CapAU$70.13m
Earnings (TTM)-AU$19.66m
Revenue (TTM)AU$6.30m

11.1x

P/S Ratio

-3.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AVR income statement (TTM)
RevenueAU$6.30m
Cost of RevenueAU$1.83m
Gross ProfitAU$4.48m
ExpensesAU$24.14m
Earnings-AU$19.66m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.44
Gross Margin71.04%
Net Profit Margin-311.96%
Debt/Equity Ratio-139.7%

How did AVR perform over the long term?

See historical performance and comparison

Valuation

Is Anteris Technologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Anteris Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Anteris Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Anteris Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Anteris Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Anteris Technologies performed over the past 5 years?

10.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AVR is currently unprofitable.

Growing Profit Margin: AVR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AVR is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.

Accelerating Growth: Unable to compare AVR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AVR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: AVR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Anteris Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: AVR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AVR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AVR has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AVR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AVR has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: AVR is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.


Dividend

What is Anteris Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AVR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AVR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Wayne Paterson (54 yo)

5.42yrs

Tenure

AU$1,790,309

Compensation

Mr. Wayne G. Paterson is the Founder and Chief Executive Officer of ProCom Rx since June 2013. Mr. Paterson has been Chief Executive Officer of Anteris Technologies Ltd (formerly known as Admedus Limited)...


CEO Compensation Analysis

Compensation vs Market: Wayne's total compensation ($USD1.32M) is above average for companies of similar size in the Australian market ($USD300.22K).

Compensation vs Earnings: Wayne's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AVR's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: AVR's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.4%.


Top Shareholders

Company Information

Anteris Technologies Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Anteris Technologies Ltd
  • Ticker: AVR
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$70.130m
  • Shares outstanding: 8.06m
  • Website: https://www.anteristech.com

Location

  • Anteris Technologies Ltd
  • Toowong Tower
  • Suite 302
  • Toowong
  • Queensland
  • 4066
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/14 15:44
End of Day Share Price2021/10/14 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.